Caris Life Sciences

Caris Life Sciences^® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence^®, the company’s healthcare information and comprehensive tumor profiling service with more than 70,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. The company is also developing its ADAPT Biotargeting System^™ technology, a revolutionary and proprietary blood-based platform for the development of novel therapeutics, drug delivery and drug target identification. The platform is also being developed for diagnosis, prognosis, and theranosis of cancer and other complex diseases.

Caris also maintains the Center of Excellence Network for Precision Medicine (“COE Network”) which was established to promote the appropriate study and use of molecular profiling in the diagnosis and treatment of cancer with leading cancer centers in the United States. Headquartered in the Dallas-Fort Worth Metroplex, Caris Life Sciences offers services throughout Europe, the U.S., Australia and other international markets.